Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Thank you for choosing ACROBiosystems. Would you rate our product and service? Thank you for choosing ACROBiosystems. Would you rate our product and service?
Here come GMP Grade Cytokines!Free Sample is available! Here come GMP Grade Cytokines!Free Sample is available!
Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
GDF15 mAb - 01 | PCC | Metabolism | Solid tumor,Cancer cachexia |
Immobilized Mouse GDF-15, His Tag (Cat. No. GD5-M5149) at 1 μg/mL (100 μL/well) can bind Human GFR alpha-like, Fc Tag (Cat. No. GFE-H5259) with a linear range of 0.3-10 ng/mL (QC tested).
The purity of Biotinylated Human GDF-15, Avitag, Fc Tag (Cat. No. GD5-H82F9) is more than 85% and the molecular weight of this protein is around 80-95 kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
NGM-120 | NGM-120 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Anorexia; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Cachexia; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Visugromab | CTL-002 | Phase 2 Clinical | CatalYm GmbH | Solid tumours; Urinary Bladder Neoplasms | Details |
Ponsegromab | PF-06946860 | Phase 2 Clinical | Pfizer Inc | Ovarian Neoplasms; Heart Failure; Fatigue; Pancreatic Neoplasms; Anorexia; Feeding and Eating Disorders; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung | Details |
GDF15 agonist (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus | Details | |
NN-9215 | Human-GDF15; MIC-1; NN-9215; LA-GDF15 | Phase 1 Clinical | Novo Nordisk A/S | Obesity | Details |
CIN-109 | CIN-109; JNJ-9090 | Phase 1 Clinical | Janssen Sciences Ireland Unlimited Company | Obesity | Details |
AV-380 | AV-380 | Phase 1 Clinical | Aveo Pharmaceuticals Inc | Cachexia | Details |
NGM-120 | NGM-120 | Phase 2 Clinical | Ngm Biopharmaceuticals Inc | Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Stomach Neoplasms; Anorexia; Pancreatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Cachexia; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
Visugromab | CTL-002 | Phase 2 Clinical | CatalYm GmbH | Solid tumours; Urinary Bladder Neoplasms | Details |
Ponsegromab | PF-06946860 | Phase 2 Clinical | Pfizer Inc | Ovarian Neoplasms; Heart Failure; Fatigue; Pancreatic Neoplasms; Anorexia; Feeding and Eating Disorders; Breast Neoplasms; Prostatic Neoplasms; Colorectal Neoplasms; Cachexia; Carcinoma, Non-Small-Cell Lung | Details |
GDF15 agonist (Lilly) | Phase 1 Clinical | Eli Lilly And Company | Diabetes Mellitus | Details | |
NN-9215 | Human-GDF15; MIC-1; NN-9215; LA-GDF15 | Phase 1 Clinical | Novo Nordisk A/S | Obesity | Details |
CIN-109 | CIN-109; JNJ-9090 | Phase 1 Clinical | Janssen Sciences Ireland Unlimited Company | Obesity | Details |
AV-380 | AV-380 | Phase 1 Clinical | Aveo Pharmaceuticals Inc | Cachexia | Details |
This web search service is supported by Google Inc.